Healthcare provider profile · identity verified

Xiaobo Wang, M.D.

Internal Medicine · LIVERMORE, CA · NPI 1548551682

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	440	156
Amlodipine Besylate	Amlodipine Besylate	231	79
Levothyroxine Sodium	Levothyroxine Sodium	217	69
Losartan Potassium	Losartan Potassium	209	74
Lisinopril	Lisinopril	205	70
Hydrochlorothiazide	Hydrochlorothiazide	148	50
Atenolol	Atenolol	143	49
Metformin Hcl Er	Metformin Hcl	143	47
Fluticasone Propionate	Fluticasone Propionate	122	57
Alendronate Sodium	Alendronate Sodium	109	35
Metoprolol Tartrate	Metoprolol Tartrate	108	39
Gabapentin	Gabapentin	95	34
Famotidine	Famotidine	91	42
Trazodone Hcl	Trazodone Hcl	82	25
Terazosin Hcl	Terazosin Hcl	79	23
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	78	18
Albuterol Sulfate Hfa	Albuterol Sulfate	70	38
Simvastatin	Simvastatin	67	23
Furosemide	Furosemide	63	23
Tamsulosin Hcl	Tamsulosin Hcl	61	23
Metoprolol Succinate	Metoprolol Succinate	60	22
Sertraline Hcl	Sertraline Hcl	58	21
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	56	17
Allopurinol	Allopurinol	50	17
Alvesco	Ciclesonide	49	23
Doxycycline Monohydrate	Doxycycline Monohydrate	48	40
Jardiance	Empagliflozin	48	15
Azelastine Hcl	Azelastine Hcl	46	14
Omeprazole	Omeprazole	45	21
Pantoprazole Sodium	Pantoprazole Sodium	45	17
Hydralazine Hcl	Hydralazine Hcl	41	16
Glipizide Er	Glipizide	38	12
Potassium Chloride	Potassium Chloride	38	16
Oxycodone Hcl	Oxycodone Hcl	33	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	32	suppressed
Fluocinonide	Fluocinonide	31	17
Rosuvastatin Calcium	Rosuvastatin Calcium	30	12
Glipizide	Glipizide	29	suppressed
Montelukast Sodium	Montelukast Sodium	29	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	29	11
Pradaxa	Dabigatran Etexilate Mesylate	28	13
Clobetasol Propionate	Clobetasol Propionate	27	16
Ibuprofen	Ibuprofen	26	16
Pravastatin Sodium	Pravastatin Sodium	26	suppressed
Metformin Hcl	Metformin Hcl	25	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	25	suppressed
Cephalexin	Cephalexin	23	21
Isosorbide Mononitrate Er	Isosorbide Mononitrate	22	suppressed
Citalopram Hbr	Citalopram Hydrobromide	21	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	21	suppressed
Lovastatin	Lovastatin	21	suppressed
Tramadol Hcl	Tramadol Hcl	21	suppressed
Finasteride	Finasteride	20	suppressed
Amoxicillin	Amoxicillin	19	14
Hydrocortisone	Hydrocortisone	19	12
Lorazepam	Lorazepam	19	suppressed
Mirtazapine	Mirtazapine	19	suppressed
Morphine Sulfate Er	Morphine Sulfate	19	suppressed
Tizanidine Hcl	Tizanidine Hcl	19	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	19	13
Ketoconazole	Ketoconazole	18	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	17	suppressed
Humalog Kwikpen U-100	Insulin Lispro	17	suppressed
Humulin N	Insulin Nph Human Isophane	17	suppressed
Metronidazole	Metronidazole	17	suppressed
Warfarin Sodium	Warfarin Sodium	17	suppressed
Prednisone	Prednisone	16	13
Ropinirole Hcl	Ropinirole Hcl	16	suppressed
Acyclovir	Acyclovir	15	suppressed
Memantine Hcl	Memantine Hcl	15	suppressed
Temazepam	Temazepam	15	suppressed
Azithromycin	Azithromycin	14	14
Carvedilol	Carvedilol	14	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	14	14
Meloxicam	Meloxicam	14	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	14	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Naproxen	Naproxen	13	suppressed
Diazepam	Diazepam	12	suppressed
Olanzapine	Olanzapine	12	suppressed
Rizatriptan	Rizatriptan Benzoate	12	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	12	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Veo Insulin Syringe	Syrge-Ndl,ins 0.3 Ml Half Mark	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error